Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 4:35 PM
Ignite Modification Date:
2025-12-25 @ 2:26 PM
NCT ID:
NCT05405166
Pre Assignment Details:
A total of 531 participants were randomized in a 1:1 ratio to receive isatuximab (Isa) either via intravenous (IV) or subcutaneous (SC) route in combination with pomalidomide and dexamethasone (Pd). Interim results are presented up to primary completion date (PCD) of 06-Nov-2024. Reasons for study discontinuation at PCD are presented. Each cycle=28 days.
Recruitment Details:
This study was conducted at 120 sites in 21 countries. A total of 637 participants were screened from 23-Jun-2022 to 13-May-2024, of which 106 were screen failures. Screen failures were mainly due to not meeting eligibility criteria.
Study:
NCT05405166
Study Brief:
Results Section:
NCT05405166